The BMM Strategic Research Agenda was completed after a thorough process and consultation of leading experts in the field. Five research lines have been defined, each focusing on the research and development of materials and their therapeutic application:

• RL1-Cardiovascular: biomaterials for the treatment of vascular diseases, and passive and bioactive scaffolds for the functional restoration and regeneration of arteries, heart valves and myocardial tissue.
• RL2-Musculoskeletal: biomaterials for the functional restoration of degenerative musculoskeletal tissues, in particular spine and articular joints.
• RL3-Nephrology: biomaterials for the prevention and treatment of kidney dysfunction, including reduction, refinement and replacement of haemodialysis therapy.
• RL4-Coatings: coatings for (implantable) medical devices, to prevent and/or treat inflammation and infections, and/or to improve cardiovascular and musculoskeletal interventions and therapies.
• RL5-Drug delivery: biomaterials for the targeted drug delivery in oncology and controlled drug release in chronic diseases.

Each research line addresses a clear clinical need and envisions specific biomedical materials breakthroughs. Within the research lines, focal areas have been selected on the basis of their impact on public healthcare and on the economic and societal relevance.